Oculis Holding AG (OCS) Quarterly Institutional 13F Update (Q2 2026)

OCS ranks #5737 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

OCS is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

OCS is a top-conviction position for EQT Fund Management S.a r.l. — at 11.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Israel Englander has added to its OCS position for two straight quarters, increasing it by $28.0M to reach $28.3M today.

Pivotal bioVenture Partners Investment Advisor LLC has trimmed its OCS position for two straight quarters, cutting it by $24.8M while still holding $20.9M.

OCS is down 0.6% today, but institutions show net buying of $109.1M this quarter — a divergence between today's price move and the underlying institutional flow.

OCS reported a net loss of $99.0M in its latest fiscal year.

• Not yet profitable — net loss of $99.0M in the latest fiscal year
• Net income declined year over year, from -$85.8M to -$99.0M
• Operating cash flow was negative, using $66.3M in cash
• Current ratio of 5.96x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.20x equity — within a conventional range